Semaglutide: what the published research shows

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed for type 2 diabetes and obesity, and it is the active compound supplied in our catalogue as semaglutide. The published literature describes it as a potent, long-acting GLP-1 receptor agonist with therapeutic efficacy in type 2 diabetes and obesity, and analytical reviews note increasing demand for methods to identify it in pharmaceutical formulations and biological matrices [9].

The work summarised below centres on the GLP-1 receptor and its downstream effects on metabolic, cardiovascular, and neuropsychiatric endpoints, with study populations ranging from postpartum individuals with recent gestational diabetes to adults with schizophrenia, older adults with type 2 diabetes, and youth with severe obesity.

Research Studies

Semaglutide and cardiometabolic risk after gestational diabetes

A registered effectiveness-implementation Hybrid Type 1 randomised clinical trial is evaluating immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM) [1]. A total of 226 postpartum individuals with recent GDM are randomised 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, is assessed at 6 months postpartum. Participants then enter a 6-month maintenance phase in which semaglutide continuation, discontinuation, or initiation reflects patient and clinician decisions [1].

Semaglutide and cardiometabolic profile in schizophrenia with metabolic syndrome

Patients with schizophrenia on second-generation antipsychotics carry a high burden of metabolic syndrome and elevated cardiovascular risk, with few effective treatment options [2]. A multicentre, double-blind, placebo-controlled randomised trial is evaluating whether adjunctive oral semaglutide 3 mg once daily, added to treatment as usual, reduces 10-year cardiovascular risk (QRISK3) and improves insulin resistance, lipids, weight, and metabolic biomarkers over 24 weeks compared with placebo, while confirming psychiatric safety and tolerability [2].

Semaglutide and muscle preservation in older adults starting therapy

A randomised, double-blind, placebo-controlled trial is evaluating whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care [3]. Participants receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6; secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, and resting metabolic rate [3].

Semaglutide and switching to zovaglutide in adults with obesity

The HORIZON-SWITCH-SZ study is evaluating the safety and tolerability of continuing treatment with zovaglutide injection following titration to 2.4 mg semaglutide injection in adult participants with obesity [4].

Semaglutide dose effects on metabolic and stress hormones, craving, and alcohol use

A study is examining two doses of semaglutide, 1.0 mg and 2.0 mg, versus placebo in patients with alcohol use disorder (AUD) and obesity (Ob) to assess whether these doses improve alcohol craving, stress, and alcohol use outcomes [5].

Semaglutide and zenagamtide in excess body weight

A research study is investigating how well zenagamtide helps people with excess body weight lose weight compared to semaglutide [6].

Semaglutide reinitiation after sleeve gastrectomy in youth

A Phase 3a, randomised, parallel-controlled trial is comparing early reinitiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery) [7]. The trial involves 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants are randomised to semaglutide 2.4 mg weekly or standard care for 24 months, with outcomes assessed at 1 month, day of surgery, and 1, 3, 6, 9, 12, 18, and 24 months postoperatively [7].

Semaglutide and structured lifestyle support in postmenopausal breast cancer survivors

A phase IV trial is studying whether adding semaglutide to structured lifestyle support improves heart and blood vessel health in postmenopausal obese breast cancer survivors taking an aromatase inhibitor [8]. In this population, obesity raises the risk of heart and blood vessel problems. The structured lifestyle support includes counselling on nutrition and physical activity with specific recommendations for individuals to follow [8].

Semaglutide in analytical and real-world contexts

Analytical reviews report that semaglutide is a potent long-acting GLP-1 receptor agonist with outstanding therapeutic efficacy for type 2 diabetes and obesity, and that its widespread clinical use has driven demand for techniques to identify it in pharmaceutical formulations and biological matrices [9]. A community pharmacy-based cross-sectional survey in Denmark investigated treatment patterns among adult users of semaglutide for weight management, noting that users may not follow the recommended treatment regimen [10]. A separate analysis examined neuropsychiatric outcomes with tirzepatide, semaglutide, and other GLP-1 receptor agonists, noting that neuropsychiatric safety concerns including depression and suicidal ideation have emerged during expanding clinical use, and that whether risks differ across successive generations of incretin-based therapies remains uncertain [11]. A pooled analysis of placebo-controlled STEP trials examined gallbladder-related adverse events with semaglutide 2.4 mg [12].

If you are reading this for personal health reasons

This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes — https://clinicaltrials.gov/study/NCT07797036
• [2] Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome — https://clinicaltrials.gov/study/NCT07770282
• [3] HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide — https://clinicaltrials.gov/study/NCT07760948
• [4] A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) — https://clinicaltrials.gov/study/NCT07812597
• [5] Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes — https://clinicaltrials.gov/study/NCT07772960
• [6] A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide — https://clinicaltrials.gov/study/NCT07668414
• [7] Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth — https://clinicaltrials.gov/study/NCT06934655
• [8] Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors — https://clinicaltrials.gov/study/NCT07769047
• [9] Analytical methods for the determination of semaglutide in pharmaceutical formulations and biological matrices: A comprehensive review — https://pubmed.ncbi.nlm.nih.gov/42664897/
• [10] Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey — https://pubmed.ncbi.nlm.nih.gov/42443134/
• [11] Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists — https://pubmed.ncbi.nlm.nih.gov/42420795/
• [12] Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials — https://pubmed.ncbi.nlm.nih.gov/42410302/